Table 5.
Incremental cost-effectiveness ratio (ICER) for sensitivity analyses
| Parameter |
Routine vaccination |
Routine and a catch-up vaccination |
|---|---|---|
| US$ per QALYs | US$ per QALYs | |
| Base case |
219 |
450 |
| Cost per year of life saved (no quality of life adjustments) |
253 |
503 |
| HPV16/18-related cervical diseases only |
448 |
698 |
| Duration of vaccine protection = 20 years |
Dominated1 |
656 |
| Vaccine coverage= 50% for routine and 60% for catch-up |
106 |
250 |
| Vaccine coverage= 95% for routine and 98% for catch-up |
258 |
425 |
| High cost of vaccine series (increased by 25%) |
406 |
686 |
| High cost of treating HPV-related disease (increased by 25%) |
86 |
326 |
| Low cost of treating HPV-related disease (decreased by 25%) |
350 |
573 |
| Discounted at 0% |
Cost saving |
Cost saving |
| Discounted at 5% |
900 |
1201 |
| Pessimistic scenario2 | Dominated1 | 998 |
1 A strategy is “weakly” dominated if a more effective strategy has a lower incremental cost-effectiveness ratio.
2 Pessimistic scenario assumes low HPV-related disease cost (decreased by 25%), 20 years of vaccine protection, and high health utilities (0.97 for HPV-related disease).